CLINICAL STUDY: ACUTE CORONARY SYNDROMES
Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina
Steven P. Schulman, MD*,*,
David R. Thiemann, MD*,
Pamela Ouyang, MD, FACC*,
Nisha C. Chandra, MD*,
Douglas S. Schulman, MD, FACC ,
Steven E. Reis, MD, FACC ,
Michael Terrin, MD ,
Sandra Forman, MA,
Cicero Piva de Albuquerque, MD||,
Raymond D. Bahr, MD, FACC¶,
Susan N. Townsend, BSN*,
Rosalie Cosgriff, RCT* and
Gary Gerstenblith, MD, FACC*
* Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Allegheny General Hospital, Pittsburgh, Pennsylvania USA
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Maryland Medical Research Institute, Baltimore, Maryland, USA
|| Unidade Coronariana-InCor, Sao Paulo, Brazil
¶ St. Agnes Medical Center, Baltimore, Maryland USA
Manuscript received April 10, 2001;
revised manuscript received August 27, 2001,
accepted October 18, 2001.
* Reprint requests and correspondence: Dr. Steven P. Schulman, Johns Hopkins Hospital, Carnegie 568, 601 North Wolfe Street, Baltimore, Maryland 21287, USA.
SSCHULM{at}JHMI.edu
OBJECTIVES: We tested whether acute hormone therapy reduces ambulatory electrocardiographic ischemia in postmenopausal (PMP) women with unstable angina (UA).
BACKGROUND: Endothelial dysfunction contributes to the pathophysiology of UA. Acute estrogen administration improves endothelial function in PMP women with coronary artery disease and increases coronary artery blood flow.
METHODS: Two hundred ninety-three PMP women with UA (mean age 69.7 years), treated with standard anti-ischemic therapy, were enrolled within 24 h of symptom onset. In a double-blind fashion, subjects were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days or placebo. The primary end point was the number of ambulatory electrocardiographic ischemic events over the first 48 h. Clinical events were also determined over six months of follow-up.
RESULTS: Electrocardiographic ischemia did not differ among the three randomized groups. The mean number of ischemic events per patient over 48 h was 0.74 for estrogen, 0.86 for estrogen plus progesterone and 0.74 for the placebo groups (p = 0.87). The percentage of patients with ischemic events and the mean duration of ischemia did not differ between hormone- and placebo-treated patients. In-hospital and six-month rates of adverse clinical events were also similar among the three randomized groups.
CONCLUSIONS: Acute hormone therapy does not reduce ischemia in PMP women with UA when added to standard anti-ischemic therapy.
|
Abbreviations and Acronyms
| | ACS | | acute coronary syndromes | | CAD | | coronary artery disease | | E | | conjugated equine estrogen | | ECG | | electrocardiogram | | GP | | glycoprotein | | HERS | | Heart and Estrogen/progestin Replacement Study | | MI | | myocardial infarction | | MPA | | medroxyprogesterone | | PCI | | percutaneous coronary intervention | | PLBO | | placebo | | PMP | | postmenopausal | | UA | | unstable angina |
|
This article has been cited by other articles:
|
|
|
|
 
E. S.H. Kim, T. P. Carrigan, and V. Menon
Enrollment of Women in National Heart, Lung, and Blood Institute-Funded Cardiovascular Randomized Controlled Trials Fails to Meet Current Federal Mandates for Inclusion
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
672 - 673.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ouyang, E. D. Michos, and R. H. Karas
Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1741 - 1753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Shaw, C. N. Bairey Merz, C. J. Pepine, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, S. Mankad, B. L. Sharaf, et al.
Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3_Suppl_S):
S4 - S20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Mieres, L. J. Shaw, A. Arai, M. J. Budoff, S. D. Flamm, W. G. Hundley, T. H. Marwick, L. Mosca, A. R. Patel, M. A. Quinones, et al.
Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Coronary Artery Disease: Consensus Statement From the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association
Circulation,
February 8, 2005;
111(5):
682 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Waters, D. Gordon, J. E. Rossouw, R. O. Cannon III, P. Collins, D. M. Herrington, J. Hsia, R. Langer, L. Mosca, P. Ouyang, et al.
Women's Ischemic Syndrome Evaluation: Current Status and Future Research Directions Report of the National Heart, Lung and Blood Institute Workshop : October 2-4, 2002 : Section 4: Lessons From Hormone Replacement Trials
Circulation,
February 17, 2004;
109
(6):
e53 - e55.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Filippatos and J. T. Parissis
Estrogen administration in patients with chronic heart failure: not ready for prime time
Eur J Heart Fail,
March 1, 2003;
5(2):
113 - 116.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kirschstein
Menopausal Hormone Therapy: Summary of a Scientific Workshop
Ann Intern Med,
February 18, 2003;
138(4):
361 - 364.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Adamopoulos, D. Leftheriotis, E. Sbarouni, G. Karavolias, and D. T. Kremastinos
Acute haemodynamic effects of oestrogen administration in male patients with chronic heart failure
Eur J Heart Fail,
December 1, 2002;
4(6):
719 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C Stevenson and M. I Whitehead
Hormone replacement therapy
BMJ,
July 20, 2002;
325(7356):
113 - 114.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Group for the Women's Health Initiative In
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
JAMA,
July 17, 2002;
288(3):
321 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Waters
Estrogen therapy for unstable angina: Another bump for the bandwagon
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
238 - 240.
[Full Text]
[PDF]
|
|
|
|
